XTL Acquires Stake In iviGene

XTL Biopharmaceuticals Ltd has acquired a stake in U.S.-based iviGene Corporation. The acquisition gives XTL access to iviGene‘s proprietary IVIAT technology for identifying novel drug targets for treating a broad range of infectious diseases. The technology is expected to enable XTL to develop both novel human monoclonal antibody and small molecule drugs for antiviral, antibacterial Read more about XTL Acquires Stake In iviGene[…]

Epimmune Licenses Gene Delivery Technologies

Epimmune Inc. has licensed Valentis, Inc.’s proprietary PINC gene delivery technology for Epimmune’s preventive and therapeutic DNA vaccines in development against the human immunodeficiency virus (HIV) and the hepatitis C virus (HCV). Valentis has granted Epimmune a non-exclusive license to certain patented and non-patented technology for use in developing DNA vaccines against HIV and HCV Read more about Epimmune Licenses Gene Delivery Technologies[…]

Corixa Receives Grant To Develop Tuberculosis Vaccine

Corixa Corporation has been awarded a $2.3 million Challenge Grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a new candidate vaccine for the treatment of tuberculosis. As a result, Corixa will conduct preclinical and clinical testing of a new candidate vaccine produced using M. tuberculosis proteins, combined with formulations developed Read more about Corixa Receives Grant To Develop Tuberculosis Vaccine[…]

vaccine technology

Epimmune Receives Patent For Vaccine Technology

Epimmune Inc. announced that the U.S. Patent and Trademark Office has issued the Company a patent relating to the Company’s core vaccine technology. The patent is U.S. Patent Number 6,037,135 entitled “Methods of Making HLA Binding Peptides and Their Uses,” and it includes claims covering methods for using any genomic or protein sequence to discover Read more about Epimmune Receives Patent For Vaccine Technology[…]

anti-infective

ArQule And Genome Therapeutics Sign Anti-infective Agreement

ArQule, Inc. and Genome Therapeutics have announced a new drug discovery collaboration uniting their key strengths in the genomics and chemistry fields. ArQule will use their new Parallel Track Drug Discovery program to screen and optimise compounds against an expanded number of proprietary validated anti-infective targets which Genome Therapeutics has derived from its PathoGenome Database. Read more about ArQule And Genome Therapeutics Sign Anti-infective Agreement[…]

Prodigene Announces Milestone In Nih Collaboration

ProdiGene, Inc. announced at the Keystone Symposia, that it successfully expressed a sub unit vaccine in maize that is expected to produce an immune response to simian immunodeficiency virus (SIV), the primate equivalent to HIV.The research is funded by an Innovation Grant program from the NIH Institute of Allergy and Infectious Disease’s Office of AIDS Read more about Prodigene Announces Milestone In Nih Collaboration[…]

iomai corporation

Berna And Iomai Announce Collaboration

Berna Biotech Ltd. and Iomai Corporation have announced a collaboration for the development of vaccines for administration using a skin patch. The collaboration will pool Berna’s expertise in the development of vaccines and novel adjuvants with Iomai’s expertise in skin delivery using its proprietary patch technology. Needle-free delivery has become a global priority because of Read more about Berna And Iomai Announce Collaboration[…]

RiboTargets LTD

RiboTargets And Sun Microsystems Collaborate

RiboTargets and Sun Microsystems Inc. have entered into a collaboration using high-powered computing methods to discover a novel class of antibiotic. In the collaboration, Sun committed a 200 processor SUN TCF (Technical Compute Farm) on which RiboTargets has been running its unique virtual screening software RiboDock. The software is designed to screen huge numbers of Read more about RiboTargets And Sun Microsystems Collaborate[…]

bioenvision

Bioenvision Completes Acquisition Of Pathagon

Bioenvision has closed its acquisition of Pathagon, a privately held company focused on the development of novel anti-infective products and technologies. With the acquisition, Bioenvision adds to its portfolio the rights to two FDA approved and marketed anti-infective technologies, OLIGON (TM) and methylene blue. Dr. Chris Wood MD, Bioenvision’s President & CEO, commented, “we are Read more about Bioenvision Completes Acquisition Of Pathagon[…]

AVANT Immunotherapeutics

Avant Licenses Vaccine Technology

AVANT Immunotherapeutics, Inc. has signed a license agreement with DynPort Vaccine Company LLC (DVC) for exclusive rights to use certain components of AVANT’s vaccine technology. DVC, a private company, is chartered with providing an integrated approach for the advanced development of specific vaccines and other products to protect against the threat of biological warfare agents. Read more about Avant Licenses Vaccine Technology[…]

Shopping Dragon Pharmaceutical Online

Cypionat 250

Injectable Anabolic Steroid
Main Chemical Name: Testosterone Cypionate
Produced by: Dragon Pharma Labs
Package: 1 X 10 ml (250 mg/ml)

Trenbolone 200

Injectable Anabolic Steroid
Primary Component: Trenbolone Enanthate
Producer: Dragon Pharma
Package: 1 X 10 ml (200 mg/ml)

Cut Mix 150

Injectable Anabolic Steroid
Active Component: Testosterone Propionate, Drostanolone Propionate, Trenbolone Acetate
Manufacturer: Dragon Pharmaceutical
Unit: 1 X 10 ml (150 mg/ml)

Masteron 200 - Bulk Price

Administration: Injection
Basal Constituent: Drostanolone Enanthate
Producer: Dragon Pharmaceuticals
Package: 10 x 10 mL vial (200 mg/mL)
Price: 10 x $67.00

EQ 500

Injectable Steroid for Muscle Growth
Prime Substance: Boldenone Undecylenate
Producer: Dragon Pharma Labs
10 mL Sterile Multi-dose Vial (500 mg/mL)

Cut Mix 150

Injectable Steroid for Muscle Growth
Mix of: Testosterone Propionate,
Drostanolone Propionate, Trenbolone Acetate
Produced by: Dragon Pharma
10 mL Sterile Multi-dose Vial (150 mg/mL)

Cut Mix 150 [10 Vials]

Injectable Steroid for Muscle Growth
Mix of:
- 50mg Testosterone Propionate
- 50mg Drostanolone Propionate
- 50mg Trenbolone Acetate
Producer: Dragon Pharmaceuticals
10 Vials [10 mL per Vial (150 mg/ml)]
Price: 10 x $52.00 = $520.00 in Total

EQ 500

Active Ingredient: Boldenone Undecylenate
Produced by: Dragon Pharma
Amount: 10 mL vial (500 mg/mL)

Nolvadex

Basic Component: Tamoxifen Citrate
Manufacturer: Dragon Pharma LLC
Package: 100 tabs (20 mg/tab)

Trenbolone 200

Prime Component: Trenbolone Enanthate
Manufacturer: Dragon Pharmaceuticals
Unit: 10 x 10 mL vial (200 mg/mL)

Clenbuterol

Prime Substance: Clenbuterol Hydrochloride
Made by: Dragon Pharmaceuticals
Amount: 100 pastilles (40 mcg/pastille)

Sustanon 350

Basal Substance: Testosterone Blend
Manufacturer: Dragon Pharma LLC
Package: 10 x 10 mL vial (350 mg/mL)